Right on the heels of its IPO, Insilico Medicine is starting the year with an oncology discovery and development pact with French pharma Servier.  | Right on the heels of its IPO, Insilico Medicine is ...

The startup’s filing comes during a broader biotech recovery that’s made some industry watchers optimistic IPOs could rebound ...

Big Pharma-backed Aktis Oncology has announced plans to go public, in the latest encouraging sign for those betting on a ...

A wave of China out-licensing deals is feeding a biotech comeback in Hong Kong, where IPOs and follow-on placements are ...

One of the biotech industry’s most esteemed venture capitalists anticipates that, after two years of drought, a wave of drug ...

The biotech, which has a deal with Eli Lilly worth as much as $1.1 billion, is developing two targeted radiopharmaceuticals ...

Hong Kong reclaims IPO leadership as tech and biotech listings surge Hong Kong tops global IPOs as AI, biotech and robotics ...

The IPO market for new technology listings picked up in 2025. So far this year, at least 23 U.S.-based companies have listed ...

Jyong Biotech Ltd. (Revived IPO) (MENS) is planning to raise $22 million in an initial public offering (IPO) on Thursday, April 3rd, IPO Scoop reports. The company plans to issue 2,700,000 shares at ...

Drug developers aren’t expected to come back to the US equity markets in full force until next year — lagging other industries as biotechnology has delivered only subpar investor returns. Only five ...

Small and mid-cap biotech stocks entered 2025 like a compressed spring, and it finally snapped higher— here's why.

While access to capital funding remains elusive for many biotechs and the macroeconomic environment remains uncertain due to tariffs, M&A remains strong and should ramp up in the second half of the ...